论文部分内容阅读
选取我院收治的糖尿病肾病(DN)患者92例,随机分为治疗组和对照组各46例。对照组在糖尿病肾病常规治疗措施的基础上,加用替米沙坦片口服。治疗组则联合使用前列地尔注射液静脉滴注和替米沙坦片口服。结果:尿素氮、血肌酐、空腹血糖和治疗前对比,差异均没有统计学意义;两组患者治疗后的24小时尿蛋白定量、平均动脉压均显著低于治疗前(均P<0.05);治疗组治疗后的24小时尿蛋白定量为(101.39±12.03)mg,显著低于对照组治疗后(P<0.05)。结论:前列地尔联合替米沙坦可显著降低DN患者的尿蛋白水平,保护患者的肾功能,延缓病情的进展。
A total of 92 patients with diabetic nephropathy (DN) admitted to our hospital were randomly divided into treatment group (46 cases) and control group (46 cases). Control group in the conventional treatment of diabetic nephropathy based on the addition of telmisartan tablets orally. The treatment group was treated with alprostadil injection intravenously and telmisartan tablets orally. Results: There was no significant difference in blood urea nitrogen, serum creatinine and fasting blood glucose before and after treatment. Urine protein and mean arterial pressure in 24 hours after treatment in both groups were significantly lower than those before treatment (all P <0.05). Urinary protein in 24 hours after treatment in the treatment group was (101.39 ± 12.03) mg, which was significantly lower than that in the control group after treatment (P <0.05). Conclusion: Alprostadil combined with telmisartan can significantly reduce urinary protein levels in patients with DN, protect patients with renal function and delay the progression of the disease.